CRAF

Consolidated Credit Announces Director of Housing Counseling Election To Community Reinvestment Alliance of Florida Board

Retrieved on: 
Monday, March 18, 2024
Community, CRAF, Tobon, Credit, Housing, Outreach, Senior counsel, Rehabilitation

FORT LAUDERDALE, Fla., March 18, 2024 /PRNewswire/ -- Consolidated Credit announces the election of Sandra Tobon, Director of Housing Counseling & Community Outreach for Consolidated Credit, to the Community Reinvestment Alliance of Florida Board.

Key Points: 
  • FORT LAUDERDALE, Fla., March 18, 2024 /PRNewswire/ -- Consolidated Credit announces the election of Sandra Tobon , Director of Housing Counseling & Community Outreach for Consolidated Credit, to the Community Reinvestment Alliance of Florida Board.
  • The Community Reinvestment Alliance of Florida (CRAF) stands as a distinguished coalition of community leaders representing diverse stakeholders, unified in their dedication to advocating for fair and equal access to financial services, products, and increased community investments.
  • "Representing Consolidated Credit on the Board of the Community Reinvestment Alliance of Florida is an esteemed honor.
  • Tobon oversees the planning, monitoring, and evaluation of all housing counseling services and community outreach activities at Consolidated Credit.

TEAMSTERS PILOTS AT OMNI AIR VOTE OVERWHELMINGLY TO AUTHORIZE A STRIKE

Retrieved on: 
Thursday, February 8, 2024
RLA, International Brotherhood of Teamsters, Omni Air International, ATSG, Defense, ABX Air, Civil Reserve Air Fleet, Railway Labor Act, Atmosphere of Earth, Airline, ACMI, Air Transport Services Group, Aircraft, CRAF

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- Omni Air International (Omni Air) pilots who are represented by the Airline Professionals Association-Teamsters Local 1224 voted to authorize a strike, with 100 percent of participating members voting in favor of the action. Today's strike authorization allows Teamsters Local 1224's leadership to call a strike on behalf of the pilot group, if necessary and when legally permitted under the Railway Labor Act (RLA).

Key Points: 
  • WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- Omni Air International (Omni Air) pilots who are represented by the Airline Professionals Association-Teamsters Local 1224 voted to authorize a strike, with 100 percent of participating members voting in favor of the action.
  • "This overwhelming vote should be a clear wake up call to Omni's management team that enough is enough," said Captain Paul Rodell, a member of the Omni Air Pilots Executive Council.
  • Omni Air pilots have been in negotiations for an amended collective bargaining agreement for nearly three years.
  • Air Transport Services Group, Inc. (NASDAQ: ATSG) acquired Omni Air in 2018 and operates two other airlines, ABX Air, Inc. and Air Transport International, Inc.
    Omni Air's 350 pilots are represented by the Airline Professionals Association, Teamsters Local 1224, which represents pilots and flight crew members from five airlines operating across the country.

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Retrieved on: 
Monday, May 15, 2023
Carcinoma, Insurance, KRAS, AACR, NF2, N-acetyllactosaminide 3-alpha-galactosyltransferase, Quarter, Half-life, Therapeutic index, SOS1, BRAF, Fast Track, Bristol Myers Squibb, Research, MEK, SHP2, AstraZeneca, PI3K, TEAD, Plasma, Patient, Investment, RAS, Data, AHR, FDA, Collaboration, CRAF, IND, Conference, RAF, Vaccine, Pharmaceutical industry, Life insurance, Cryptocurrency, EGFR, Hippopotamus

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points: 
  • Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date
    BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023.
  • “The start to 2023 has been full of exciting developments, including external clinical validation of the Hippo pathway and targeting TEAD.
  • “The first quarter also was the first time we shared the novel profile of IK-595, our MEK-RAF complex inhibitor.
  • Collaboration revenue was $5.3 million and $3.4 million for the three months ended March 31, 2023 and 2022, respectively.

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 14, 2023
Research, AACR, TEAD, Fast Track, ERK, American Association for Cancer Research, EORTC, Prevalence, Cell, Phosphorylation, NF2, Patient, EGFR, FDA, Gene expression, RAS, Invasive urothelial carcinoma, MEK, Clinical trial, CRAF, Cancer, Pharmacokinetics, Carcinoma, IND, Mesothelioma, Nivolumab, Pharmaceutical industry, Vaccine, Antibiotics, Cryptocurrency, Hippopotamus

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2022. The Company also provided an update across the organization and pipeline.

Key Points: 
  • “We’re thrilled to report the meaningful progress made in 2022 across our entire pipeline.
  • “In 2022 we also advanced our efforts in the RAS pathway – one of the highest spaces of unmet medical need – with our nomination of IK-595, targeting MEK-RAF.
  • Research and development expenses were $64.3 million and $47.1 million for the year ended December 31, 2022 and 2021, respectively.
  • General and administrative expenses were $22.2 million and $18.0 million for the year ended December 31, 2022 and 2021, respectively.

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Retrieved on: 
Tuesday, March 7, 2023
IND, RAF, ARAF, MEK, Cancer, NRAS, PI3K, AML, Poster, SOS1, RAS, Conference, AACR, American Association for Cancer Research, BRAF, MAPK, EGFR, Investigational New Drug, SHP2, KRAS, Lung, ERK, Phosphorylation, CRAF, Pharmaceutical industry

Dr. Zhang will present at a plenary session on Wednesday, March 8.

Key Points: 
  • Dr. Zhang will present at a plenary session on Wednesday, March 8.
  • The RAS pathway is implicated in at least half of a million new cancer diagnoses each year in the United States alone.
  • Presentation and poster details are as follows:
    More details on the conference program can be found on the conference website .
  • Ikena’s poster presentation will be available on the Resources section of the company’s website following the conference.

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

Retrieved on: 
Friday, December 9, 2022
Annual report, Melanoma, NYSE, SAN, Security (finance), NVS, RAS, Cancer, BRAF, Form 10-K, Research, ID, Safety, CRAF, COVID-19, Patient, Pharmaceutical industry, NRAS, Novartis

SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into an exclusive worldwide license agreement with Novartis (NYSE: NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRAS mutant (NRASm) melanoma and other RAS/MAPK pathway-driven tumors. To date, naporafenib has been dosed in over 500 patients across multiple trials and has demonstrated preliminary clinical proof-of-concept as well as favorable safety and tolerability data both as a single agent and in combination with other molecularly targeted and immuno-oncology therapies.

Key Points: 
  • As separately announced, Erasca has priced a $100 million equity offering with select healthcare investors.
  • Under the terms of the license agreement, in exchange for an exclusive worldwide license to develop and commercialize naporafenib, Erasca will pay to Novartis a one-time upfront cash payment of $20 million and $80 million of shares in Erasca common stock at a price of $6.50 per share.
  • Novartis is also eligible to receive a low single-digit percentage royalty on net sales of naporafenib.
  • Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Verastem Oncology Appoints Rob Gagnon to Board of Directors

Retrieved on: 
Thursday, December 15, 2022
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, MIT Sloan School of Management, Mirati, RAF, RAMP, Management, FAK, Oncology, Amgen, Harvard Bioscience, NSCLC, Security (finance), Controller, Food, Regenerative medicine, RAS, LLP, Regulation of tobacco by the U.S. Food and Drug Administration, Bentley University, ARAF, Cancer, BRAF, Government, Biogen, Clean Harbors, MEK, MBA, Research, Breakthrough therapy, Patent, CRAF, PricewaterhouseCoopers, Patient, KRAS, Hospital, Pharmaceutical industry, Medical imaging, Verastem Oncology

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022.
  • I am excited to contribute to Verastem in this new capacity by joining the distinguished and dedicated Board of Directors and contribute to Verastems continued progress.
  • Mr. Gagnon has more than 20 years of financial and commercial experience in heading global finance operations.
  • Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Retrieved on: 
Monday, November 28, 2022
US Foods, Doctor of Philosophy, Combination therapy, RAF, IND, Bristol Myers Squibb, Corporate development, RAS, Patient, TEAD, CRAF, Half-life, Hippopotamus, Research, AHR, MEK, FDA, Pharmaceutical industry, MD

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development candidate in the RAS pathway.

Key Points: 
  • The RAS pathway is implicated in at least half a million new cancer diagnosis each year in the United States alone.
  • Ikena aims to target the pathway on multiple levels, including preventing known resistance mechanisms to achieve deep and sustained responses.
  • Ikenas new development candidate, IK-595, traps MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors.
  • I am thrilled to announce this addition to our pipeline, one that adds to our holistic approach to the Hippo & RAS oncosignaling network.

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, International, Verastem Oncology, Executive, FDA, Pancreatic Cancer Action Network, KRAS, Geron Corporation, Large-cell lung carcinoma, Table, Research, U.S. Securities and Exchange Commission, Mirati, Partnership, SEC, Program, Company, GAAP, Food, MEK, Intellectual property, CEO, Mission statement, Security (finance), Patient, Cancer, INN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Government, USAN, Part, Review, Breakthrough therapy, RAS, Pancreatic cancer, Strategic management, CRAF, RAF, United States Adopted Name, Investment, International nonproprietary name, RAMP, Patent, Safety, NSCLC, FAK, ARAF, Everolimus, Amgen, Oncology, BRAF, Pharmaceutical industry, Medical imaging, Video game, Bank

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2022, and highlighted recent progress.
  • Verastem Oncology ended the three months ended September 30, 2022 (2022 Quarter) with cash, cash equivalents and investments of $104.0 million.
  • Research and development expenses for the 2022 Quarter were $11.3 million, compared to $9.3 million for the 2021 Quarter.
  • Selling, general and administrative expenses for the 2022 Quarter were $6.4 million, compared to $5.5 million for the 2021 Quarter.

Verastem Oncology Appoints Anil Kapur to Board of Directors

Retrieved on: 
Thursday, October 20, 2022
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Actinium, CRAF, Regulation of tobacco by the U.S. Food and Drug Administration, RAMP, Birla Institute of Technology, Mesra, Program, NSCLC, Patent, ARAF, Board of directors, Shire, Mirati, Oncology, Baxalta, Amgen, MS, Commercial, MBA, Executive, Cancer, Fuqua School, Company, Marketing, FAK, Biomarker, Duke University, Verastem Oncology, Organization, Breakthrough therapy, Security (finance), Johnson & Johnson, Industrial engineering, Board, U.S. Securities and Exchange Commission, Government, Triple accreditation, SEC, MEK, Neoplasm, Patient, Business, BRAF, RAF, RAS, KRAS, Food, Geron Corporation, Strategic management, Louisiana Tech University, Bristol Myers Squibb, Management, Medical imaging, Pharmaceutical industry, Technology, Director

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Anil Kapur to its Board of Directors, effective October 20, 2022.
  • Anils deep experience in oncology and his track record of product launch and commercial operations excellence will be invaluable as Verastem works to bring its lead compound RAF/MEK clamp VS-6766 in combinations across RAS-driven tumors to patients, said Michael Kauffman, M.D., Ph.D., Lead Director of the Verastem Oncology Board of Directors.
  • I am pleased to welcome Anil to the Board of Directors and believe he will be a tremendous source of strategic insights and guidance.
  • Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.